Luigina Guasti, Giuseppe Derosa, Stefano Fumagalli, Marc Ferrini, Riccardo Asteggiano
{"title":"Hypertension management in the elderly and the very elderly.","authors":"Luigina Guasti, Giuseppe Derosa, Stefano Fumagalli, Marc Ferrini, Riccardo Asteggiano","doi":"10.1093/eurjpc/zwaf194","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension increases with age, with a very high prevalence in older patients. Since hypertension is a major contributor of cardiovascular diseases, this condition accounts for the majority of stroke and a relevant number of coronary artery disease cases in the older adults. Ageing is associated with frailty and multimorbidity, often associated with polypharmacy, which may complicate the management of hypertension. Specific diseases like diabetes and Parkinson disease associated with autonomic dysfunctions, and the frail condition, should be carefully considered in order to avoid orthostatic hypotension. Aortic stenosis, cardiac hypertrophy, heart failure, reduced glomerular filtration rate, arrhythmias such as atrial fibrillation, obstructive coronaropathies and cerebral vascular lesions constitute hemodynamic challenges and may be associated with increased adverse effects during anti-hypertensive treatments. Moreover, specific drugs and drug-drug interactions are associated with sides effects particularly deleterious in the older patients. The worsening of the state of health and the increase in the degree of frailty can result either as a consequence of target-organ-damage related to hypertension or caused by antihypertensive drugs. Therefore, in the older adults, a careful assessment of the individual risk/benefit profile and a personalized view of the patient is necessary to establish the appropriate blood pressure targets and the appropriate treatments.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwaf194","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertension increases with age, with a very high prevalence in older patients. Since hypertension is a major contributor of cardiovascular diseases, this condition accounts for the majority of stroke and a relevant number of coronary artery disease cases in the older adults. Ageing is associated with frailty and multimorbidity, often associated with polypharmacy, which may complicate the management of hypertension. Specific diseases like diabetes and Parkinson disease associated with autonomic dysfunctions, and the frail condition, should be carefully considered in order to avoid orthostatic hypotension. Aortic stenosis, cardiac hypertrophy, heart failure, reduced glomerular filtration rate, arrhythmias such as atrial fibrillation, obstructive coronaropathies and cerebral vascular lesions constitute hemodynamic challenges and may be associated with increased adverse effects during anti-hypertensive treatments. Moreover, specific drugs and drug-drug interactions are associated with sides effects particularly deleterious in the older patients. The worsening of the state of health and the increase in the degree of frailty can result either as a consequence of target-organ-damage related to hypertension or caused by antihypertensive drugs. Therefore, in the older adults, a careful assessment of the individual risk/benefit profile and a personalized view of the patient is necessary to establish the appropriate blood pressure targets and the appropriate treatments.
期刊介绍:
European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.